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Abstract Education and diagnostic tests capable of early
detection represent our most effective means of preventing
transmission of human immunodeficiency virus (HIV). The
importance of early detection is underlined by studies
demonstrating increased life expectancy following early
initiation of antiviral treatment. The Elecsys HIV combi
PT assay is a fourth-generation antigen–antibody combi-
nation assay developed to allow earlier detection of sero-
conversion, and to have increased sensitivity and improved
specificity. We aimed to determine how early the assay
could detect infection compared with existing assays;
whether all HIV variants could be detected; and the assay’s
specificity using samples from blood donors, routine
specimens, and patients with potential cross-reacting
factors. Samples were identified as positive by the Elecsys
assay 4.9 days after a positive polymerase chain reaction
result (as determined by the panel supplier), which was
earlier than the 5.3–7.1 days observed with comparators.
The analytical sensitivity of the Elecsys HIV combi PT
assay for the HIV-1 p24 antigen was 1.05 IU/mL, which
compares favorably with the comparator assays. In addition,
the Elecsys assay identified all screened HIV subtypes and
displayed greater sensitivity to HIV-2 homologous antigen
and antibodies to HIV-1 E and O and HIV-2 than the other
assays. Overall, the specificity of the Elecsys assay was
99.88 % using samples from blood donors and 99.81 %
when analyzing unselected samples. Potential cross-reacting
factors did not interfere with assay performance. The
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assay that has been granted the CE mark according to
Directive 2009/886/EC.
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Introduction
Human immunodeficiency virus (HIV) is a member of the
retrovirus family. The virus is found worldwide but is most
common in Africa, with a prevalence of[15 %; prevalences
of 0.5 to\1.0 % and 0.1 to\0.5 % have been reported for the
USA and UK, respectively [1]. The virus evolves rapidly, and
two main types have been identified: HIV-1 and HIV-2, with
HIV-1 being responsible for infecting the majority of
patients. HIV-1 is further subdivided, based on genetic vari-
ation, into three main groups, M (major), O (outlier), and N
(non-M, non-O), with type M having nine subtypes (A, B, C,
D, F, G, H, J, and K); there are then at least six sub-subtypes
(A1–A4, F1, and F2) [2, 3]. These HIV groups and subtypes
have a distinct geographic distribution. HIV-2 is less infective
and is generally confined to particular parts of, or areas with a
strong association with, West Africa; in North America and
Western Europe, HIV-1 group M subtype B is the most pre-
valent subtype, while subtype A is most common in Eastern
Europe and Central Asia, and subtype C is most common in
India. In addition, some variants result from a recombination
event between two or more different subtypes, and a new
group of HIV-1, group P, has recently been identified [2, 4].
Transmission of HIV is by contact with bodily fluids, such
as blood, semen, and vaginal secretions, and can occur via
unprotected sex, unscreened blood transfusions, or through
sharing needles [3]. HIV can also be transmitted from mother
to child during pregnancy, delivery, or by breast-feeding [5].
Once infected, patients remain infected for life as the viral
genome integrates into the DNA of host cells. The major
target cells are CD4? T lymphocytes that are a vital part of
the immune system. The function of the immune system
becomes compromised as these cells are destroyed [3].
During the first few weeks after infection, patients can
experience non-specific influenza-like symptoms, such as
fever and aching muscles, which resolve within a month.
During this time, known as the primary infection (often
1–3 weeks, but sometimes up to 10 weeks after infection),
there is a peak in viral RNA and p24 antigen that is
detectable in the patient’s serum. Seroconversion occurs in
general about 25 days after infection, and immunoglobulin
(Ig) M followed by IgG antibodies to viral proteins become
detectable in serum. A next phase follows in which the
patient is asymptomatic while viral RNA in the plasma
declines and stabilizes at a value called ‘viral set point’, and
p24 antigen is no longer detectable. In the final phase, and
once the immune system has been compromised, patients
become susceptible to opportunistic infections and exhibit
the symptoms known as the acquired immunodeficiency
syndrome (AIDS). At this stage of the disease, the viral
RNA level rises again, while p24 antigen may reappear and
antibodies to viral gag and pol proteins may no longer be
detectable in serum samples from the patient [6, 7].
Given the lack of a cure for HIV infection, preventing
transmission is paramount. The highest risk of transmission
is during the very early stage of infection due to the high
concentration of HIV in the blood and genital secretions
[8]. Furthermore, the patient is probably unaware that he/
she is infected and so may not be taking precautions. Also,
despite the lack of symptoms during the asymptomatic
phase, medium to high concentrations of HIV are often
present in the blood leading to a continued high risk of
transmission. Hence, education regarding prevention of
transmission and tests capable of detecting as soon as
possible whether or not someone is infected are important
factors in the management of HIV prevention.
Although there is no cure, viral suppression with anti-
viral therapy can maintain immune function and reduce
both mortality and the effect of opportunistic infections [9].
Early initiation of treatment has been shown to increase life
expectancy, adding to the need to detect infection early in
the disease course [10].
The fourth-generation assays were developed to allow
earlier detection of HIV seroconversion and reduce the time
period to positive virus detection [11–13]. More recently, the
ElecsysHIV combi PT assay (Roche Diagnostics, Penzberg,
Germany) has been developed as an update to the previous
assay; it differs from the Elecsys HIV combi assay as it
includes a pre-treatment step to improve specificity and
increase sensitivity to HIV-1 p24 antigen, thereby improving
early detection of HIV infection. This assay contains a spe-
cial set of anti-p24 antibodies that allow early detection of
infection, late-phase infection, and detection of p24 antigen
derived from HIV-1 group O and HIV-2. In addition, the
assay contains a set of antigens including gp41, gp36, HIV-1
RT, and HIV-2 RT in order to provide high sensitivity to anti-
HIV-1 and anti-HIV-2 antibodies, as well as enhanced
security for detecting antibodies against all subtypes
(including circulating recombinant forms of HIV and HIV-1
subtype O). Other fourth-generation HIV assays are also
available, such as the ARCHITECT HIV Ag/Ab combo
(Abbott Laboratories, Wiesbaden, Germany), AxSYMHIV
Ag/Ab combo (Abbott Laboratories, Wiesbaden, Germany),
and ADVIA Centaur HIV Ag/Ab combo (Siemens
Healthcare Diagnostics Inc, Deerfield, USA) assays.
The aim of this study was to determine whether the
Elecsys HIV combi PT assay can reliably detect infection
with all investigated HIV variants, and at the earliest
possible stage of infection. The specificity of the assay
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using samples from blood donors, routine specimens, and
patients with potential cross-reacting factors (such as from
patients with elevated rheumatoid factor (RF), autoanti-
bodies or monoclonal gammopathy, or other viral infec-
tions) was also determined.
Materials and methods
The study was carried out at 12 centers: Central Institute for
Blood Transfusion and Immunology, University Hospital
Innsbruck, Innsbruck, Austria; MVZ Stein und Partner,
Mo¨nchengladbach, Germany; MVZ Wagnerstibbe fu¨r
Laboratoriumsmedizin, Gyna¨kologie, Humanmedizin und
Pathologie GmbH, Go¨ttingen, Germany; De´partement de
Me´decine de Laboratoire, Service d’Immunologie et Aller-
gie, Centre Hospitalier Universitaire Vaudois, Lausanne,
Switzerland; Department of Transfusion Medicine, Siriraj
Hospital and Medical School, Mahidol University, Bangkok,
Thailand; Centro de Transfusion de Galicia, Santiago de
Compostela, Spain; Ospedaliero di Dolo, Servizio di Medi-
cina di Laboratorio, Dolo, Italy; St. Vincent’s Centre for
Applied Medical Research, St. Vincent’s Hospital Sydney,
Darlinghurst NSW, Australia; Swedish Institute for Infec-
tious Control SMI, Department of Virology, Solna, Sweden;
MVZ Labor Mu¨nchen Zentrum, Munich, Germany; Hospital
Fernando Da Fonseca, Lisbon, Portugal; and Roche R&D,
Penzberg, Germany.
Elecsys HIV combi PT assay
The assay is performed according to the sandwich princi-
ple. During the first incubation, any HIV particle available
within the sample is lysed to release the p24 antigen.
During the second incubation, a sandwich complex is
formed between anti-HIV antibodies and the biotin- and
ruthenium-labeled HIV-specific antigens, and between p24
antigen and the biotin- and ruthenium-labeled monoclonal
anti-p24 antibodies. Following the addition of streptavidin-
coated microparticles, the third incubation allows the
complexes to bind to the solid phase as a result of the
interaction between biotin and streptavidin. The bound
microparticles are then magnetically captured onto the
surface of an electrode, and unbound material is removed.
Chemiluminescent emission is induced by applying a
voltage to the electrode and measured by a photomultiplier.
The results are automatically determined by the Elecsys
software that compares the signal produced from the
sample with the cutoff value obtained during system cali-
bration. The total assay time is 27 min [14].
In this study, the Elecsys HIV combi PT assay was
performed on the Elecsys 2010, e411, or MODULAR
Analytics E170 immunoassay analyzer.
Comparator assays
The comparator assays used, namely the Abbott ARCHI-
TECT HIV Ag/Ab combo, Abbott AxSYM HIV Ag/Ab
combo, Abbott PRISM HIV O Plus, and Siemens ADVIA
Centaur HIV Ag/Ab combo assays, are registered with
European Notified Bodies and represent state-of-the-art
HIV screening assays. Assays were performed and inter-
preted according to the manufacturers’ instructions. Each
assay is described briefly below.
The ARCHITECT HIV Ag/Ab combo assay uses
monoclonal mouse antibodies and HIV antigen-coated
microparticles to bind the antigens and antibodies within
the sample. These are then bound to acridinium-labeled
conjugates, and a trigger solution is added to initiate a
chemiluminescent reaction that is measured by the
ARCHITECT system [15].
The AxSYM HIV Ag/Ab combo assay also uses
microparticle enzyme immunoassay technology. Recom-
binant E. coli HIV antigens and mouse anti-HIV p24
monoclonal antibodies coated on microparticles bind HIV
antigens and antibodies from the sample. Biotin-labeled
recombinant antigens, peptides, and anti-p24 monoclonal
antibodies react with the captured antibodies/antigens and
are detected using an anti-biotin:alkaline phosphatase
conjugate; the fluorescence produced on the addition
of 4-methylumbelliferyl phosphate is measured by the
AxSYM system [16].
The PRISM HIV O Plus assay detects HIV antibodies
using a three-step sandwich procedure. Microparticles coated
with HIV antigens are used to bind to antibodies in the sample
and are captured on a glass fiber matrix. Biotinylated peptides
and proteins and an acridinium-labeled anti-biotin conjugate
are added, followed by an alkaline hydrogen peroxide solu-
tion to generate a chemiluminescent signal [17].
In the ADVIA Centaur HIV Ag/Ab combo assay,
antibodies or antigens within the patient sample are bridged
to antigens and antibodies provided with the assay. Strep-
tavidin-coated microparticles and biotinylated recombinant
antigens are used to capture the antigens and antibodies,
and acridinium ester-labeled recombinant antibodies/anti-
gens are then added to generate relative light units for
detection on the ADVIA Centaur analyzer [18].
Samples
Samples stored in aliquots at -20 C were used for
sensitivity testing, and only one freeze/thaw cycle was
permitted. Fresh samples from blood donors and samples
taken routinely from hospitalized patients and patients with
potential cross-reacting factors were tested in parallel with
the comparator assay. Sensitivity and specificity were
determined using the following sample types.
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Commercial seroconversion panels
Seroconversion panels used to analyze early infection were
purchased from SeraCare Life Sciences Inc (Milford,
MA, USA; n = 8: PRB929, PRB930, PRB940, PRB943,
PRB957, PRB964, PRB965, PRB966) and Zeptrometrix
Inc (Buffalo, NY, USA; n = 6: HIV 9012, HIV 9016, HIV
9021, HIV 9023, HIV 9034, HIV 6243). These panels
comprised samples taken from patients before and after
they tested positive for HIV infection and throughout the
immune response.
Samples from patients in the early stage of infection
Sequential samples taken from patients soon after infection
were available to the centers in Lausanne (59 samples from
24 patients) and Sydney (30 samples from 15 patients) and
were used to assess sensitivity.
NIBSC/WHO p24 antigen standard
The Elecsys HIV combi PT, ARCHITECT HIV Ag/Ab
combo, ADVIA Centaur HIV Ag/Ab combo, and
AxSYM HIV Ag/Ab combo assays were assessed against
the NIBSC/WHO p24 antigen standard (NIBSC 90/636)
using the following dilutions: 0.000, 0.625, 1.250, 2.500,
5.000, and 10.000 IU/mL. Samples were diluted with
human donor plasma that was negative for all HIV sero-
logic markers.
HIV subtypes
Samples were known to be antibody positive for HIV-1
group M subtypes (n = 609), HIV-1 group O subtypes
(n = 8), or HIV-2 (n = 472) as a result of immunoblot
testing, sequencing the pol amplicon spanning the whole
protease and first 1,200 nucleotides of the reverse
transcriptase open reading frame, or using an immuno-
logical in vitro enzyme test for determining HIV-1
subtypes A–E.
In addition, serial dilutions of 28 lysate samples derived
from culture supernatants and representing different HIV
variants were tested. The lysates were known to contain
antigens from HIV-1 subtypes A–H, O, or HIV-2, or
antibodies to HIV-1 subtypes A–G, O, or HIV-2.
Blood donations
Fresh serum samples or EDTA plasma from unselected
blood donors were used for the specificity analyses. Any
discrepant sample was retested, and a confirmatory assay
was used for any repeatedly reactive sample.
Daily routine samples
Fresh serum or EDTA plasma samples collected from
hospitalized patients, outpatients, pre-surgery patients,
dialysis patients, pregnant women, and for anonymous
testing were used for the specificity analyses. All samples
were unselected.
Potential cross-reaction
A total of 148 samples from patients containing potential
cross-reacting factors were used. These samples were
selected as they were from patients with RF [200 IU/mL,
autoantibodies or monoclonal gammopathy, or who had
antibodies to other viral infections that may have interfered
with the performance of the assays (Epstein–Barr virus
IgM, Epstein–Barr virus IgG, cytomegalovirus IgM, cyto-
megalovirus IgG, herpes simplex virus IgM, herpes simplex
virus IgG, and influenza vaccine).
Data analysis
Prior to the start of all evaluations, each center performed a
system and reagent familiarization with run-to-run, inter-
assay precision.
Results were obtained from single measurements where
possible. Initially reactive samples were retested in single
measurements or double determinations, while repeatedly
discrepant and positive samples were measured against
confirmatory assays. Results were expressed as s/co ratios.
Results were deemed to be negative if the s/co \0.9 and
positive if the s/co C1.0. An s/co between 0.9 and \1.0
was considered to fall within a ‘gray zone’; this 10 % gray
zone was introduced during the data validation, and sam-
ples in this zone were considered positive. Results obtained
from the comparator assays were interpreted according to
the information provided by the manufacturer [15–18].
Data on early detection were calculated using the Paul
Ehrlich Institute model, as reported by Courouce´ et al. [19].
Seroconversion panels comprising serial samples from
patients before and after they tested positive for HIV
infection were assessed using the immunoassays. The PCR
data used to determine positivity were provided by the
panel suppliers and were obtained using the following
assays: Procleix HIV-1/HCV assay (Gen-Probe Inc.),
COBAS Amplicor HIV-1 Monitor (Roche), HIV-1 bDNA
(Chiron/Siemens), and COBAS AmpliPrep/COBAS
TaqMan HIV Test v1.0 (Roche); a PCR test is the most
sensitive for HIV detection and can detect HIV infection
before seroconversion. The Paul Ehrlich Institute model
calculates the time difference between the PCR test iden-
tifying the sample as positive and the immunoassay
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reporting a positive result. In this model, seroconversion is
theoretically possible the day after the last negative test
result [19]. Hence, if the PCR test and immunoassay both
detect the same panel sample as positive, the difference is
0, whereas if the first sample identified by the immunoas-
say as positive was taken 4 days after the sample identified
as positive by the PCR test, the difference is 4. The total
and the average numbers of days of detection after a
positive PCR result were calculated.
Results
Sensitivity: commercial seroconversion panels
A total of 14 seroconversion panels (comprising 135
samples) were analyzed to determine how soon after a
positive PCR result the immunoassays could detect HIV
infection. The results are given in Table 1 and show that
the Elecsys assay detects HIV infection at a similar or
shorter time interval than the comparator assays.
Additional data calculated using all assessments of the
Elecsys HIV combi PT assay are available for a total of
90 seroconversion panels; these results were calculated
irrespective of the comparator assay used (and, in some
cases, a comparator was not used). These data support the
findings given in Table 1 and show that the total number of
days to a positive Elecsys test result after a positive
polymerase chain reaction (PCR) result was 493 days,
giving a mean delay of 5.478 days (Roche, data on file).
Sensitivity: samples from patients in the early stage
of infection
Samples from 15 patients were tested using the Elecsys
HIV combi PT and ARCHITECT HIV Ag/Ab combo
assays by the group in Sydney. Both assays identified 29
HIV-positive bleedings out of a total of 30 bleedings,
giving a number of patient panels/positive bleedings of
0.517.
The group in Lausanne tested 59 samples from 24
patients using the Elecsys HIV combi PT assay and
identified 58 as HIV positive giving a number of patient
panels/positive bleedings of 0.414. Of these 24 patients, 19
had detectable HIV p24 antigen but were negative for IgM
and IgG (pre-seroconversion), and two were positive for
IgM before being positive for IgG (IgM seroconversion);
for two patients, it was not possible to distinguish between
the previous two categories. The remaining patient was at a
later stage of seroconversion. Samples from one patient
were found to be positive on day 0 but negative on day 13.
Sensitivity: NIBSC/WHO p24 antigen standard
Results using the NIBSC/WHO p24 antigen standard
dilution series and the Elecsys HIV combi PT assay
showed a linear relationship. The analytical sensitivity of
the Elecsys HIV combi PT assay was calculated to be
1.05 IU/mL, which compares favorably with the compar-
ator assays. The analytical sensitivities calculated during
this study for comparator assays were the following:
0.94 IU/mL for the ARCHITECT HIV Ag/Ab combo;
Table 1 Seroconversion
sensitivity data using the Paul
Ehrlich Institute calculation
method
Day of bleeding with first
positive results (last negative
sample ? 1 day) compared
with PCR data provided by the
panel suppliers (SeraCare and
Zeptometrix). The first positive
bleed with the PCR assay was
considered to be day 0
Seroconversion
panel
Elecsys HIV
combi PT
ADVIA Centaur HIV
Ag/Ab combo
AxSYM HIV
Ag/Ab combo
ARCHITECT HIV
Ag/Ab combo
PRB929 0 4 0 0
PRB930 0 3 0 0
PRB940 0 7 0 0
PRB943 2 7 2 2
PRB957 2 9 14 9
PRB964 7 8 7 7
PRB965 7 7 12 5
PRB966 9 13 9 9
HIV 9012 16 16 16 16
HIV 9016 3 3 3 3
HIV 9021 4 4 4 4
HIV 9023 7 7 7 7
HIV 9034 5 5 5 5
HIV 6243 7 7 7 7
Total number
of days
69 100 86 74
Mean number
of days
4.929 7.143 6.143 5.286
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1.89 IU/mL for the ADVIA Centaur HIV Ag/Ab combo;
and 1.20 IU/mL for the AxSYM HIV Ag/Ab combo.
Sensitivity: HIV subtypes
A summary of the sensitivity of the Elecsys HIV combi
PT assay for detecting HIV subtypes is shown in Table 2.
The assay correctly identified all investigated HIV-1 and
HIV-2 subtypes.
The Elecsys assay recognized both antigen and anti-
bodies to all investigated HIV subtypes over a series of
dilutions (Table 3). In addition, the Elecsys HIV combi
PT assay showed greater sensitivity than at least one of the
comparator assays for detecting HIV-2 antigen and anti-
bodies to HIV-1 E, O, and HIV-2.
Specificity: samples from blood donors
The specificity of the Elecsys HIV combi PT assay
determined using samples from blood donors at the indi-
vidual centers was as follows: Innsbruck, 99.86 %
(n = 2,834); Bangkok, 99.93 % (n = 1,500); Santiago de
Compostela, 99.87 % (n = 1,524); and Dolo, 99.87 %
(n = 1,485).
Overall, the specificity of the Elecsys HIV combi PT
assay was 99.88 % (n = 7,343) and showed a clear dis-
crimination between positive and negative samples. In
addition, the specificity of the Elecsys HIV combi PT
assay using samples from blood donors was comparable to
that of other assays; examples of the comparisons are
shown in Table 4.
Specificity: routine samples
The specificity of the Elecsys HIV combi PT assay
determined in routine samples at the individual centers
was as follows: Mo¨nchengladbach, 99.80 % (n = 1,000);
Go¨ttingen, 100 % (n = 1,004); Lausanne, 99.71 %
(n = 347); Sydney, 100 % (n = 249); Munich, 99.42 %
(n = 700); Lisbon, 99.78 % (n = 467); and Penzberg,
100 % (n = 336).
A total of 4,103 samples from unspecified patients,
dialysis patients, and pregnant women were used to
investigate the specificity of the Elecsys HIV combi PT
assay. In this group, the overall specificity of the Elecsys
HIV combi PT assay was found to be 99.81 % (repeatedly
reactive). Examples of the specificity compared with other
assays are shown in Table 5.
Specificity: potential cross-reaction
Samples from patients with potential cross-reacting factors
were tested to analyze specificity. The Elecsys HIV
combi PT assay correctly identified the majority of the
samples as being HIV negative (147/148). The samples
tested were from patients with RF elevation [200 IU/mL
(21/21 HIV negative), autoantibodies (various; 21/21 HIV
negative) or monoclonal gammopathy (20/21 HIV nega-
tive), or from patients positive for the following (but HIV
negative): Epstein–Barr virus IgM (10/10 HIV negative),
Epstein–Barr virus IgG (10/10 HIV negative), cytomega-
lovirus IgM (10/10 HIV negative), cytomegalovirus IgG
(15/15 HIV negative), herpes simplex virus IgM (10/10
HIV negative), herpes simplex virus IgG (15/15 HIV
negative), and influenza vaccine (15/15 HIV negative).
Discussion
In this study, the Elecsys HIV combi PT assay showed
good sensitivity and specificity in a wide range of samples
and compared well with existing assays.
Early detection of infection is vital for patient man-
agement and the prevention of HIV transmission. The
fourth-generation assays can detect HIV nearly 6 days
before the third-generation assays and sometimes before
p24 antigen-only assays, and less than 3 days after nucleic
acid tests [20, 21]. In a previous report by Kwon et al., the
ARCHITECT combo assay detected infection 4–26 days
earlier than third-generation assays [22]. In our study,
positive samples could be identified by the Elecsys HIV
combi PT assay as early as 4.9 days after a positive PCR
result (using the Paul Ehrlich Institute methods as descri-
bed by Courouce´ et al. [19]), compared with 5.3–7.1 days
for the comparator assays (not significant).
Table 2 Summary of the sensitivity of the Elecsys assay for
identification of HIV subtypes in antibody-positive samples
Elecsys HIV combi
PT (tested/positive)
HIV-1 group M subtypes
A, A1, A2, A/B, A/C, A/E/C, CRF02_AG 72/72
B, B/A, B/C, CRF14_BG 262/262
C, C/A, C/B, C/E 168/168
D 16/16
E, E/A/C, E/C, E/D, CRF01_AE (=E) 59/59
F 7/7
F1 2/2
G 16/16
H 1/1
J 1/1
CRF06_cpx 1/1
CRF11_cpx 1/1
CRF13_cpx 3/3
HIV-1 group O subtypes 8/8
HIV-2 472/472
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Table 3 Dilution of lysate
samples derived from culture
supernatants at which the assays
positively detect (s/co C1.0)
specific HIV subtype antigen or
antibody
a Two different antibody samples
were tested for each subtype
HIV
subtype
Elecsys HIV
combi PT
ADVIA centaur
HIV Ag/Ab combo
AxSYM HIV
Ag/Ab combo
ARCHITECT
HIV Ag/Ab combo
HIV antigen
A 1:64,000 1:64,000 1:64,000 1:128,000
B 1:37,280 1:18,640 1:37,280 1:37,280
C 1:26,720 1:26,720 1:26,720 1:53,440
D 1:21,280 1:21,280 1:21,280 1:42,560
E 1:31,968 1:7,992 1:31,968 1:63,936
F 1:15,936 1:15,936 1:7,968 1:15,936
G 1:52,896 1:26,448 1:52,896 1:105,792
H 1:11,376 1:11,376 1:11,376 1:22,752
O 1:256 Failed to detect
diluted antigen
1:128 1:512
HIV-2 1:64 Failed to detect
diluted antigen
1:8 Failed to detect
diluted antigen
HIV antibodya
A 1:170,000 1:17,000 1:17,000 1:17,000
A 1:5,000 1:5,000 1:5,000 1:500
B 1:15,000 1:1,500 1:1,500 1:1,500
B 1:120,000 1:120,000 1:120,000 1:120,000
C 1:100,000 1:10,000 1:100,000 1:10,000
C 1:200,000 1:200,000 1:200,000 1:200,000
D 1:50,000 1:5,000 1:5,000 1:5,000
D 1:28,500 1:28,500 1:28,500 1:2,850
E 1:50,000 1:500 1:5,000 1:500
E 1:50,000 1:5,000 1:5,000 1:500
F 1:22,800 1:228 1:2,280 1:2,280
F 1:100,000 1:100,000 1:100,000 1:100,000
G 1:35,000 1:35,000 1:35,000 1:3,500
G 1:140,000 1:140,000 1:14,000 1:14,000
O 1:10,000 Failed to detect
diluted antibody
1:10,000 1:1,000
O 1:500,000 Failed to detect
diluted antibody
1:5,000 1:5,000
HIV-2 1:50,000 1:500 1:5,000 1:500
HIV-2 1:60,000 1:600 1:6,000 1:6,000
Table 4 Specificity analyses of samples from blood donors; data from Bangkok, Innsbruck, and Santiago de Compostela
Bangkok Innsbruck Santiago de Compostela
Elecsys HIV
combi PT
ARCHITECT
HIV Ag/Ab combo
Elecsys HIV
combi PT
ARCHITECT
HIV Ag/Ab combo
Elecsys HIV
combi PT
PRISM HIV
O Plusa
Total number 1,500 1,500 2,834 2,834 1,524 1,524
RR C1 s/co 3 3 4 1 2 1
RR C0.9 s/co to \1.0 s/co 3 N/A 0 N/A 1 N/A
Immunoblot confirmed
positive/PCR positive
2b 2b 0 0 0 0
Number of false positives 1 1 4 1 2 1
Specificity % RR C1 s/co 99.93 99.93 99.86 99.96 99.87 99.93
Lower confidence limit (95 %; 2-sided) RR C1 99.63–100.00 99.63–100.00 99.64–99.96 99.80–100.00 99.53–99.98 99.63–100
RR repeatedly reactive, N/A not applicable
a The PRISM HIV O plus assay only detects HIV antibodies (not antigen)
b One sample was HIV PCR positive with a viral load of 699 copies/mL; results for this sample were s/co 38–39 using the Elecsys assay and s/co 1.6–1.9 with the
ARCHITECT assay
Med Microbiol Immunol (2013) 202:77–86 83
123
The Elecsys HIV combi PT assay has been standard-
ized to the WHO reference standard for p24 antigen and
has an overall analytical sensitivity of 1.05 IU/mL at a cut-
off index of 1.0. This is similar to, or lower than, some of
the other assays; for example, in our study, the sensitivities
of the Abbott ARCHITECT combo and AxSYM assay
were 0.94 and 1.20 IU/mL, while a previous report gives
sensitivities of 1.24 and *2 IU/mL, respectively, for these
two assays [23]. In addition, an analytical sensitivity of
1.05 IU/mL conforms to the stringent standard required in
some countries (\2 IU/mL).
The Elecsys HIV combi PT assay identified all
investigated HIV subtypes. Results from the lysate dilution
series showed the assays to be comparable for detecting
HIV-1 A–H and O capsid antigens but that the Elecsys
HIV combi PT assay had greater sensitivity for detecting
HIV-2 antigen. With regard to sensitivity for detecting
antibody, the Elecsys HIV combi PT assay recognized
antibodies to HIV-1 E, O, and HIV-2 with greater sensi-
tivity than the other assays, and comparable sensitivity for
antibodies to the remaining subtypes.
Previous studies investigating laboratory-based (as
opposed to point-of-care based) HIV assays have docu-
mented that HIV-1 O strains and HIV-1 subtypes F and C
have not been detected by some assays, and the difficulty
in diagnosing HIV-1 group O has also been highlighted
by the case described by Henquell et al. [20, 21, 24, 25].
In the report by Malm et al. [13], the Abbott AxSYM
assay failed to detect one HIV-2 sample. In contrast, in
our study the Elecsys HIV combi PT assay correctly
identified as positive all samples containing HIV, irre-
spective of strain and subtype. Genetic variability, par-
ticularly of gp41, may affect the ability of enzyme assays
to detect HIV antibodies [26]. For this reason, additional
components were included in the Elecsys HIV combi PT
assay in addition to a pre-treatment step; our results
confirm that the modifications have enhanced the speci-
ficity and sensitivity of the assay.
In the context of blood donation screening, a highly
sensitive algorithm for detecting HIV must be used to
prevent HIV transmission via transfusions. It is possible
that the Elecsys HIV combi PT assay could be considered
for this purpose, given its high sensitivity and early
detection rate. Furthermore, the assay has been shown to
reliably detect all investigated HIV subtypes, including
HIV-2, and has good specificity in the samples from blood
donors tested to date.
Some studies have suggested that the fourth-generation
assays are associated with the rare occurrence of a second
diagnostic window during a period when antibody titers are
low and there is a reduction in antigenemia. This phe-
nomenon has been reported with several assays, including
the AxSYM HIV Ag/Ab combo and Enzymun-Test HIVT
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Combi assays [27–30]. One negative result during follow-
up was obtained when testing the sensitivity of the Elec-
sys HIV combi PT assay using samples from patients in
the early stage of infection. Overall, the Elecsys HIV
combi PT assay detected more samples as being HIV
positive earlier in the disease course, although a second
diagnostic window can potentially occur with all fourth-
generation assays. However, it is indeed a rare occurrence
as more than 1,000 samples taken very soon after infection
have been tested by the centers evaluating the assay and all
HIV-positive samples were correctly identified.
Overall, the specificity of the Elecsys HIV combi PT
assay using samples from blood donors was 99.88 %, with
an overall specificity of 99.81 % when analyzing unse-
lected samples. These results were comparable to those
obtained with the other assays tested and with the previous
reports. Malm et al. reported the specificities of the Abbott
ARCHITECT and AxSYM assays to be 99.95 and
99.91 %, respectively, while other studies have suggested
that fourth-generation assays have specificities ranging
from 98 to 100 % [13, 20–22, 31, 32]. In addition, the
Elecsys HIV combi PT assay demonstrated 100 % spec-
ificity in patients with infections other than HIV, such as
cytomegalovirus or herpes simplex virus.
The Elecsys HIV combi PT assay is a sensitive and
specific assay for the laboratory testing of HIV status, and a
first positive result can be obtained on average 4.9 days
after a PCR assay detects the presence of the virus in the
context of primary infection. On the basis of the results
presented here, the Elecsys HIV combi PT assay has been
granted the CE mark according to Directive 2009/886/EC
and is now available for use in laboratory-based testing
[14].
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